A month has gone by since the last earnings report for Edwards Lifesciences (EW) . Shares have added about 19.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Edwards Lifesciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Edwards Lifesciences Q2 Earnings ...

Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that its shareholders have today approved its previously announced return of capital by way of a reduction in stated capital of the Company. In accordance with the special resolution passed by the shareholders, the board of directors of the Company has determined that the stated capital of the Company, which is currently $39,868,761, will be reduced by up to $3 mill ...

Edwards Lifesciences' (EW) robust potential in the TAVR (Transcatheter Aortic Valve Replacement) business is poised to help it grow in the upcoming quarters. The company's decision to sell the Critical Care arm supports its goal of developing a comprehensive structural heart portfolio. Also, sound solvency instills optimism. However, rising costs and adverse currency impacts remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has dropped 11.3% against the 9.3% rise of the indu ...

The Company has prepared and mailed its management information circular (the "Circular") and related proxy materials (collectively, the "Meeting Materials") to its shareholders ("Shareholders") in connection with the special meeting of Shareholders to be held at 10:00 a.m. (Vancouver time) on August 16, 2024 (the "Meeting"). The Meeting Materials have been mailed to Shareholders of record as of July 10, 2024 (the "Record Date"). At the Meeting, Shareholders will be asked to consider, and if deemed advisable ...

Have you assessed how the international operations of Edwards Lifesciences (EW) performed in the quarter ended June 2024? For this medical device maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. Fo ...

The S&P 500 slipped 0.5% on Thursday, July 25, as tech stocks faltered for a second straight day even as data showed an uptick in GDP growth. Edwards Lifesciences shares plunged after the medtech firm cut its sales forecast for a critical heart device. Shares of ServiceNow moved higher following a strong earnings report buoyed by subscription revenue growth. Although indications of persistent economic strength temporarily took the spotlight on Thursday, boosting stocks in intraday trading, the concerns abou ...

Quest Diagnostics, carrying a Zacks Rank #2, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion exceeded the Zacks Consensus Estimate by 0.5%. DGX's historical five-year earnings growth rate of 7.4% compares favorably with the industry's 4.2%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 3.31%. Edwards Lifesciences Corporation (EW) reported adjusted earnings per share (EPS) of 7 ...

Edwards Lifesciences (NYSE:EW) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents. This just beats out Wall Street's estimate of 69 cents per share. It's also better than the 66 cents per share reported in the same period of the year prior. However, the company's revenue of $1.63 billion failed to impress investors. That comes in below analysts' estimate of $1.65 billion for the perio ...

Financial Data and Key Metrics Changes - Total company sales for Q2 2024 reached $1.6 billion, reflecting an 8% increase on a constant currency basis compared to the previous year [10] - Adjusted EPS was $0.70, while GAAP EPS was $0.61, which included one-time separation expenses related to the sale of Critical Care [36][50] - Adjusted gross profit margin was 77.1%, down from 77.7% in the same period last year, primarily due to foreign exchange impacts [39] Business Line Data and Key Metrics Changes - TAVR sales in Q2 were $1.04 billion, a 6% year-over-year increase, which was lower than expected [13] - TMTT sales reached $83 million, representing a 75% increase year-over-year, driven by the PASCAL repair system and early commercial introduction of EVOQUE [23] - Surgical structural heart sales were $264 million, up 5% from the prior year, supported by strong adoption of premium surgical technologies [29] - Critical Care sales were $246 million, increasing 7% year-over-year, led by pressure monitoring devices [30] Market Data and Key Metrics Changes - In the US, TAVR sales growth was slightly below the global constant currency growth rate, impacted by increased competition and hospital workflow pressures [16] - Outside the US, TAVR sales growth was slightly above the global average, with double-digit growth in Japan driven by SAPIEN 3 Ultra RESILIA [20] - The company anticipates TAVR sales growth for the second half of the year to be between 5% to 7%, down from previous guidance of 8% to 10% [21] Company Strategy and Development Direction - The company announced acquisitions of JenaValve and Endotronix to expand into new therapeutic areas, specifically aortic regurgitation and heart failure [12][31] - The strategic focus remains on advancing TAVR and TMTT technologies, with a commitment to improving patient care and expanding market share [45] - The company is confident in its long-term growth strategy, aiming for sustainable double-digit revenue and earnings growth [51] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that TAVR growth was below expectations due to increased competition and hospital workflow challenges, but remains optimistic about long-term opportunities [11][70] - The company is focused on improving referral and treatment rates for patients with severe symptomatic aortic stenosis through initiatives like the ENACT patient activation program [18] - Management expects minimal revenue contribution from recent acquisitions in 2025 but anticipates long-term growth opportunities from these investments [34][43] Other Important Information - The company plans to close the sale of Critical Care by late Q3 2024, with one-time costs associated with the sale impacting financials [42] - The company maintains a strong balance sheet with approximately $2 billion in cash and short-term investments as of June 30 [42] Q&A Session Summary Question: What would be compelling for early TAVR? - Management indicated that a compelling case for early intervention would need to demonstrate significant benefits, such as mortality reduction, to drive TAVR growth [56][58] Question: What is the outlook for TAVR growth? - Management acknowledged that TAVR growth has been slower than expected, but they believe hospitals will adapt and scale to support increasing volumes over time [70][74] Question: How does the company view the TAVR market's long-term potential? - Management remains confident in the long-term potential of the TAVR market, with a previously stated total addressable market of $10 billion by 2028, although they are not updating guidance at this time [95][96]

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Net Sales- Outside of the United States: $569.10 million compared to the $684.70 million average estimate based on three analysts. The reported number represents a change of -10.4% year over year. Net Sales- United States: $816.80 million versus the three-analyst average e ...